Ninth Circuit Upholds Class Certification Against Takeda in Landmark RICO Case
- The Ninth Circuit upheld class certification in a RICO case against Takeda for allegedly hiding cancer risks linked to Actos.
- Takeda faces over $7 billion in damages claims from third-party payers due to alleged fraud regarding Actos.
- The ruling emphasizes pharmaceutical accountability, potentially influencing future litigation and regulatory practices in the industry.
Legal Milestone for Takeda as Ninth Circuit Upholds Class Certification in RICO Case
In a landmark decision, the U.S. Court of Appeals for the Ninth Circuit affirms a critical class certification order in the case of Painters & Allied Trades District Council 82 Health Care Fund v. Takeda Pharmaceutical Company Limited. This ruling marks a significant development in the first-ever non-settlement national RICO class action lawsuit against a major pharmaceutical company. The certification allows a national class of third-party payers to pursue damages exceeding $7 billion from Takeda and its partner Eli Lilly, who are accused of conspiring to hide the bladder cancer risks linked to their diabetes medication, Actos (pioglitazone). Legal experts point out that the case, now entering its eleventh year, underscores a troubling legacy of fraud, supported by internal documents revealing that both companies were aware of the cancer risks as far back as 1999.
The implications of this ruling extend beyond financial liabilities, as it emphasizes the accountability of pharmaceutical companies in safeguarding public health. Following a 2011 mandate from the FDA requiring a warning about the bladder cancer risks associated with Actos, the drug's sales reportedly plummeted by 80%, underscoring the severe repercussions of the alleged concealment. The Ninth Circuit's rejection of the defendants' objections to class certification reinforces the thorough analysis conducted by the lower court, which met the necessary predominance requirement. R. Brent Wisner, managing partner at Wisner Baum LLP and national class counsel, expresses eagerness to advance to trial, highlighting the clear evidentiary foundation of deception that resulted in billions of dollars in fraudulent sales, potentially exposing millions of diabetics to a carcinogenic substance without their informed consent.
This ruling not only sets the stage for a jury trial but also establishes a crucial legal precedent in holding pharmaceutical companies accountable under the RICO Act. As the case unfolds, it serves as a warning to the pharmaceutical industry regarding the importance of transparency and ethical practices in drug marketing and safety disclosures. The outcome may influence future litigation and regulatory scrutiny, ultimately shaping the landscape of pharmaceutical accountability in the United States.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

